ArticleTransplant infectious disease : an official journal of the Transplantation Society
Clinical and Microbiological Insights Into Invasive Fusariosis Following Allogeneic Hematopoietic Stem Cell Transplantation: A 15-Year Single-Center Analysis.
Article in Transplant infectious disease : an official journal of the Transplantation Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Invasive Fusariosis-Time to Break the Mold.Transplant infectious disease : an official journal of the Transplantation SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInvasive fusariosis (IF) is a rare but often fatal mold infection in immunocompromised patients, particularly after allogeneic hematopoietic stem cell transplantation (HSCT). Despite antifungal prophylaxis and treatment, mortality remains high.
methodsWe retrospectively reviewed all allogeneic HSCT recipients for hematological malignancies at our center (2010-2024) and identified proven IF cases. Species identification was based on multigene sequencing, and antifungal susceptibility testing was performed.
resultsAmong 2359 allogeneic HSCTs, 17 proven IF cases (7.2/1000) were identified. Patients more often had prior HSCT (58.8% vs. 19.8%, p = 0.002) and were transplanted in non-complete remission (94.1% vs. 75.8%). Median onset was 19 days (range, 2-1011) posttransplant, with a median neutrophil count of 1/µL (range, 1-7097) at diagnosis; 64.7% were pre-engraftment. Prophylaxis included micafungin (n = 10), posaconazole (n = 4), and voriconazole (n = 3). Species: Fusarium solani complex (n = 11), Fusarium dimerum complex (n = 4), and Fusarium fujikuroi complex (n = 2). All isolates had high micafungin MECs (> 16 µg/mL); the median amphotericin B MIC was 4 µg/mL, voriconazole MIC > 8 µg/mL. Median overall survival was 8 days; mortality reached 82.4% by Day 84. In univariate analysis, combination liposomal amphotericin B (L-AMB) plus voriconazole (p = 0.013) and neutrophil recovery (p = 0.008) were associated with improved survival. No clear trends were noted in antifungal susceptibility between survivors and non-survivors.
conclusionsIF after allogeneic HSCT is rare but highly lethal. Despite the small sample size, outcomes were not clearly associated with MIC values. Early L-AMB plus VRCZ and neutrophil recovery may be associated with improved survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.